Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 67 results
Filters: Author is Kuritzkes, Daniel R  [Clear All Filters]
Found 67 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Paredes R, Tzou PL, van Zyl G, et al. "Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation." PLoS ONE. 2017;12(7):e0181357.
Li JZ, Chapman B, Charlebois P, et al. "Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy." PLoS ONE. 2014;9(3):e90485.
Ofotokun I, Na LH, Landovitz RJ, et al. "Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257." Clin. Infect. Dis.. 2015;60(12):1842-51.
Ribaudo HJ, Kuritzkes DR, Gulick RM. "A comparison of three initial antiretroviral AIDS regimens." N. Engl. J. Med.. 2007;357(10):1056-7.
Namazi G, Fajnzylber JM, Aga E, et al. "The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies." J. Infect. Dis.. 2018;218(12):1954-1963.

E

Andrade A, Guedj J, Rosenkranz SL, et al. "Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)." AIDS. 2015;29(18):2419-26.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Hu Z, Kuritzkes DR. "Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness." J. Acquir. Immune Defic. Syndr.. 2010;55(2):148-55.
Strongin Z, Sharaf R, D VanBelzen J, et al. "Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA." J. Virol.. 2018;92(12).
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Gallien S, Delaugerre C, Charreau I, et al. "Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia." AIDS. 2011;25(5):665-9.
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. "Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure." PLoS Pathog.. 2011;7(2):e1001303.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.

Pages